Should I buy or sell Avadel Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVDL shares. View AVDL analyst ratings or view top-rated stocks .

What is Avadel Pharmaceuticals' stock price target for 2024?

7 Wall Street research analysts have issued twelve-month target prices for Avadel Pharmaceuticals' shares. Their AVDL share price targets range from $16.00 to $29.00. On average, they predict the company's share price to reach $22.57 in the next twelve months. This suggests a possible upside of 31.0% from the stock's current price. View analysts price targets for AVDL or view top-rated stocks among Wall Street analysts .

How have AVDL shares performed in 2024?

Avadel Pharmaceuticals' stock was trading at $14.12 at the beginning of 2024. Since then, AVDL stock has increased by 22.0% and is now trading at $17.23. View the best growth stocks for 2024 here .

When is Avadel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our AVDL earnings forecast .

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) announced its quarterly earnings data on Monday, March, 4th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.04. The business earned $19.45 million during the quarter, compared to analyst estimates of $17.41 million. During the same period in the prior year, the business posted ($0.44) earnings per share.

What ETFs hold Avadel Pharmaceuticals' stock?

ETFs with the largest weight of Avadel Pharmaceuticals (NASDAQ:AVDL) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and AdvisorShares Dorsey Wright ADR ETF (AADR) . Invesco Nasdaq Future Gen 200 ETF (QQQS) .

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I) , Bank of America (BAC) , Fossil Group (FOSL) , Ciena (CIEN) , AMC Entertainment (AMC) , Chaarat Gold (CGH) , Associated British Foods (ABF) , Apollo Global Management (APO) , Amarin (AMRN) and Cypress Semiconductor (CY) .

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Claro Advisors LLC (0.01%). Insiders that own company stock include Eric J Ende, Geoffrey Michael Glass, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish and Thomas S Mchugh. View institutional ownership trends .

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AVDL

Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free AVDL Stock Alerts

$17.19

-0.80 (-4.45%)

(As of 03:26 PM ET)

Compare

Today's Range: $17.00
▼
$18.19
50-Day Range: $12.55
▼
$18.09
52-Week Range: $9.50
▼
$18.85

Volume: 660,762 shs
Average Volume: 1.24 million shs
Market Capitalization: $1.56 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $22.57

Get Avadel Pharmaceuticals alerts:

Avadel Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 31.0% Upside
$22.57 Price Target
Short Interest: Bearish
11.47% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.59
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.46) to $0.83 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.12 out of 5 stars

Medical Sector

584th out of 914 stocks

Pharmaceutical Preparations Industry

263rd out of 414 stocks

4.5

Analyst's Opinion

Consensus Rating
Avadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Avadel Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
11.47% of the outstanding shares of Avadel Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Avadel Pharmaceuticals has a short interest ratio ("days to cover") of 8.4.
Change versus previous month
Short interest in Avadel Pharmaceuticals has recently decreased by 0.76%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Avadel Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Avadel Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AVDL.

3.1

News and Social Media Coverage

News Sentiment
Avadel Pharmaceuticals has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Avadel Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 7 people have searched for AVDL on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.
MarketBeat Follows
13 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 160% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.00% of the stock of Avadel Pharmaceuticals is held by insiders.
Percentage Held by Institutions
69.19% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($0.46) to $0.83 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Avadel Pharmaceuticals is -8.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Avadel Pharmaceuticals is -8.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Avadel Pharmaceuticals has a P/B Ratio of 17.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Avadel Pharmaceuticals Stock (NASDAQ:AVDL)

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

AVDL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AVDL Stock News Headlines

April 17, 2024 | americanbankingnews.com

Avadel Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:AVDL)

April 16, 2024 | finance.yahoo.com

Avadel Pharmaceuticals plc (AVDL)

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 16, 2024 | americanbankingnews.com

Head to Head Comparison: Avadel Pharmaceuticals (NASDAQ:AVDL) versus Ventyx Biosciences (NASDAQ:VTYX)

April 13, 2024 | americanbankingnews.com

Avadel Pharmaceuticals (NASDAQ:AVDL) Stock Price Down 2.8%

April 12, 2024 | americanbankingnews.com

Traders Purchase Large Volume of Put Options on Avadel Pharmaceuticals (NASDAQ:AVDL)

April 11, 2024 | finance.yahoo.com

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Is Expected To Breakeven In The Near Future

April 10, 2024 | americanbankingnews.com

Avadel Pharmaceuticals' (AVDL) "Buy" Rating Reaffirmed at Needham & Company LLC

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 2, 2024 | seekingalpha.com

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

April 1, 2024 | globenewswire.com

Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

March 17, 2024 | finance.yahoo.com

AVDL Apr 2024 15.000 call

March 16, 2024 | finance.yahoo.com

AVDL Apr 2024 25.000 call

March 16, 2024 | finance.yahoo.com

AVDL Apr 2024 10.000 put

March 7, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Avadel Pharmaceuticals Amid Strong Q4 Performance and Promising Growth Prospects

March 5, 2024 | seekingalpha.com

Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang

March 5, 2024 | realmoney.thestreet.com

Avadel Pharmaceuticals price target raised by $2 at Oppenheimer, here's why

March 5, 2024 | msn.com

Avadel Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results

March 5, 2024 | finance.yahoo.com

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q4 2023 Earnings Call Transcript

March 4, 2024 | globenewswire.com

Avadel Pharmaceuticals Issues Statement On Patent Litigation

March 4, 2024 | finanznachrichten.de

Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 4, 2024 | globenewswire.com

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 3, 2024 | finance.yahoo.com

AVDL Mar 2024 5.000 put

March 1, 2024 | seekingalpha.com

Avadel Pharmaceuticals Q4 2023 Earnings Preview

March 1, 2024 | finance.yahoo.com

With 62% ownership, Avadel Pharmaceuticals plc (NASDAQ:AVDL) boasts of strong institutional backing

February 26, 2024 | finance.yahoo.com

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 4

February 25, 2024 | benzinga.com

Avadel Pharmaceuticals Stock (NASDAQ:AVDL) Earnings Dates and Earning Calls

See More Headlines

Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/04/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AVDL
CUSIP: N/A
CIK: 1012477
Web: www.avadel.com
Phone: (531) 901-5201
Fax: 353-1526-1077
Employees: 154
Year Founded: 2015

Price Target and Rating

Average Stock Price Target: $22.57
High Stock Price Target: $29.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +29.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-160,280,000.00
Net Margins: N/A
Pretax Margin: -574.96%
Return on Equity: -198.06%
Return on Assets: -84.51%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.64
Quick Ratio: 3.36

Sales & Book Value

Annual Sales: $27.96 million
Price / Sales: 56.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.98 per share
Price / Book: 17.81

Miscellaneous

Outstanding Shares: 90,580,000
Free Float: 86,954,000
Market Cap: $1.58 billion
Optionable: Optionable
Beta: 1.60

Social Links

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Gregory J. Divis Jr. (Age 57)
CEO & Director
Comp: $753.69k
Mr. Thomas S. McHugh (Age 59)
Senior VP, Principal Financial and Accounting Officer & CFO
Comp: $526k
Mr. Richard J. Kim (Age 55)
Chief Commercial Officer
Comp: $548.44k
Mr. Jerad G. Seurer
General Counsel & Company Secretary
Mr. Gregory J. Davis (Age 59)
VP of Corporate and Business Development
Mr. Mark W. Elrod
Vice President of Sales
Ms. Angie Woods
Vice President of People & Culture
Dr. Jordan S. Dubow M.D. (Age 45)
Consultant
Comp: $727.93k
Dr. Jason M. Vaughn
Senior Vice President of Technical Operations
Ms. Jennifer Gudeman PharmD
Senior Vice President of Medical & Clinical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AVDL Stock Analysis - Frequently Asked Questions

Should I buy or sell Avadel Pharmaceuticals stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVDL shares.
View AVDL analyst ratings or view top-rated stocks.
What is Avadel Pharmaceuticals' stock price target for 2024?: 7 Wall Street research analysts have issued twelve-month target prices for Avadel Pharmaceuticals' shares. Their AVDL share price targets range from $16.00 to $29.00. On average, they predict the company's share price to reach $22.57 in the next twelve months. This suggests a possible upside of 31.0% from the stock's current price.
View analysts price targets for AVDL or view top-rated stocks among Wall Street analysts.
How have AVDL shares performed in 2024?: Avadel Pharmaceuticals' stock was trading at $14.12 at the beginning of 2024. Since then, AVDL stock has increased by 22.0% and is now trading at $17.23.
View the best growth stocks for 2024 here.
When is Avadel Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AVDL earnings forecast.
How were Avadel Pharmaceuticals' earnings last quarter?: Avadel Pharmaceuticals plc (NASDAQ:AVDL) announced its quarterly earnings data on Monday, March, 4th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.04. The business earned $19.45 million during the quarter, compared to analyst estimates of $17.41 million. During the same period in the prior year, the business posted ($0.44) earnings per share.

What ETFs hold Avadel Pharmaceuticals' stock?: ETFs with the largest weight of Avadel Pharmaceuticals (NASDAQ:AVDL) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and AdvisorShares Dorsey Wright ADR ETF (AADR).Invesco Nasdaq Future Gen 200 ETF (QQQS).
What other stocks do shareholders of Avadel Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).
Who are Avadel Pharmaceuticals' major shareholders?: Avadel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Claro Advisors LLC (0.01%). Insiders that own company stock include Eric J Ende, Geoffrey Michael Glass, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish and Thomas S Mchugh.
View institutional ownership trends.
How do I buy shares of Avadel Pharmaceuticals?: Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVDL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis

Avadel Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Avadel Pharmaceuticals Stock (NASDAQ:AVDL)

AVDL Stock Price History

AVDL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

AVDL Stock Analysis - Frequently Asked Questions

Overall MarketRank^™